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Abstract 
OBJECTIVES: To report on the responsiveness testing and clinical utility of the 12-item Geriatric Self-
Efficacy Index for Urinary Incontinence (GSE-UI). 
DESIGN: Prospective cohort study. 
SETTING: Six urinary incontinence (UI) outpatient clinics in Quebec, Canada. 
PARTICIPANTS: Community-dwelling incontinent adults aged 65 and older. 
MEASUREMENTS: The abridged 12-item GSE-UI, measuring older adults' level of confidence for 
preventing urine loss, was administered to all new consecutive incontinent patients 1 week before their 
initial clinic visit, at baseline, and 3 months posttreatment. At follow-up, a positive rating of improvement 
in UI was ascertained from patients and their physicians using the Patient's and Clinician's Global 
Impression of Improvement scales, respectively. Responsiveness of the GSE-UI was calculated using 
Guyatt's change index. Its clinical utility was determined using receiver operating curves. 
RESULTS: Eighty-nine of 228 eligible patients (39.0%) participated (mean age 72.6+5.8, range 65–90). 
At 3-month follow-up, 22.5% of patients were very much better, and 41.6% were a little or much better. 
Guyatt's change index was 2.6 for patients who changed by a clinically meaningful amount and 1.5 for 
patients having experienced any level of improvement. An improvement of 14 points on the 12-item GSE-
UI had a sensitivity of 75.1% and a specificity of 78.2% for detecting clinically meaningful changes in UI 
status. Mean GSE-UI scores varied according to improvement status (P<.001) and correlated with changes 
in quality-of-life scores (r=0.7, P<.001) and reductions in UI episodes (r=0.4, P=.004). 
CONCLUSION: The GSE-UI is responsive and clinically useful. 
 
 
The Geriatric Self-Efficacy index for Urinary Incontinence (GSE-UI) is a new valid and reliable outcome 
measure for urinary incontinence (UI).
1
 An advantage of the GSE-UI is its ability to measure one of the 
psychological factors potentially underlying continence status: confidence or self-efficacy for preventing 
unwanted urine loss. Self-efficacy, the belief a person has in his or her ability to perform specific 
behaviors, has been shown to be an important factor for improving outcomes in other geriatric conditions, 
such as falls.
2–4
 Its application to UI is threefold: the promise that self-efficacy holds as a causal 
explanatory mechanism for UI, as an alternate therapeutic method, and as a new outcome measure to study 
the effect of UI interventions. 
Empirical research suggests a role for self-efficacy in the field of incontinence. For example, greater self-
efficacy for achieving continence may partially explain the impressive 32% to 65% reductions in UI seen 
during placebo treatment in randomized controlled pharmaceutical trials of UI.
5
 Increased self-efficacy may 
also account for some of the results of behavioral and combined modality treatment trials, whereby changes 
in urodynamic or voiding frequency parameters do not fully explain improvements in UI.
6–7
 
Although a number of UI outcome measures exist, there is substantial evidence that they are rarely used in 
clinical practice.
8,9
 As such, there is no value in creating another clinical UI tool unless it is constructed to 
meet the realities of busy clinicians and their clinical environment. Having demonstrated the reliability and 
validity of the 20-item GSE-UI, it was deemed important to create a shorter version and test its 
psychometric properties. This article reports on three specific objectives. The first is the reduction of items 
on the GSE-UI from the 20-item to the 12-item version. The second is the psychometric evaluation of the 
responsiveness of the 12-item version. The third is the evaluation of the clinical utility of the 12-item GSE-
UI, using different cutoff scores for measuring meaningful improvements in UI. 
 
METHODS 
Development of the 12-Item Index 
The creation, validity, and reliability testing of the 20-item GSE-UI have previously been described.
1
 To 
create a shorter index, 12 efficacy items were retained based on the following three criteria: a missing 
response rate (“does not apply to me” option) less than 30%; good to excellent item test–retest reliability, 
determined according to an intraclass correlation coefficient (ICC) greater than 0.6; and good patient 
comprehension, determined according to the patient's and research assistant's perspectives. Two original 
items “when walking 15 to 20 minutes” and “when taking a car ride for 30 minutes or longer” were 
eliminated based on ICCs of 0.57 and 0.59, respectively. Three items, “finding ways to distract yourself to 
overcome the urge to urinate,”“spacing out trips to the bathroom so you do not go too frequently,” and 
“running errands without having to stay near a washroom most of the time,” were eliminated based on 
problematic comprehension by respondents requiring clarification of the question by the interviewer. For 
many patients, rewording of the questions did not significantly improve comprehension. One item (“when 
you are frustrated”) was omitted because 43% of respondents indicated “does not apply to me,” and two 
items (“when you are tired” and “when you feel depressed”) had ICC and missing response item 
deficiencies. For the 12 items that were retained, phrasing and response scaling remained unchanged from 
the original index, whereby all items begin with “How confident are you that you can hold in your urine 
…” followed by a description of a specific situation10 (e.g., “when you are at home and have to go to the 
bathroom?”). Response options are presented on a 10-point horizontal visual analogue scale with three 
anchors: 0 indicating “not at all confident I can do,” 5 indicating “moderately confident I can do,” and 10 
indicating “extremely confident I can do.” Item reduction testing was performed for the English and French 
versions of the scale and yielded identical results. The 12-item GSE-UI is presented in Table A1. Using the 
Cronbach alpha coefficient, the internal consistency of the 12-item GSE-UI was excellent (0.90). 
Responsiveness and Clinical Utility Testing of the 12-Item GSE-UI 
The responsiveness and clinical utility of the abridged 12-item GSE-UI were tested on a new sample of 
participants who had not been involved in the reliability and validity testing. These were new patients 
seeking care at outpatient urology, gynecology, or geriatric incontinence clinics in Montreal and 
Sherbrooke, Quebec, between September 2006 and October 2007. Patients who were aged 65 and older and 
who had symptoms of UI as defined by one or more episodes of involuntary urinary loss during the 
previous 3 months were eligible. Exclusion criteria were evidence of cognitive impairment indicated by a 
score less than 24 on the Mini-Mental State Examination,
11
 other severe neurological or systemic 
conditions, and use of a permanent or intermittent urinary catheter. 
The names of individuals who were to be seen in the clinic were provided to the study research assistant, 
who then contacted them in the weeks before their scheduled clinic appointment to determine their 
eligibility and willingness to participate in the study. Individuals who were eligible and consented met with 
the research assistant at three separate time points: 1-week before their initial scheduled UI clinic visit, 
again at the time of their first UI clinic visit, and at 3-month follow-up. During the initial visit, the 
following were administered: the 12-item GSE-UI; the Mini-Mental State Examination; and the 
International Consultation on Incontinence Questionnaire, a validated measure that queries the individual 
regarding UI frequency and amount and the circumstances under which UI occurs.
12
 Patients were also 
instructed on how to complete a 72-hour bladder diary documenting the frequency of incontinence episodes 
and were asked to submit it at their next visit.
13 
 One week later, when patients attended their scheduled UI clinic appointment, they also met with the 
research assistant, who administered the 12-item GSE-UI for a second time. The research assistant then 
asked whether the patient had experienced a change in UI during the past week, using the Patient's Global 
Impression of Improvement scale (PGI-I). The PGI-I is a validated, single-item global rating-of-change 
scale that asks patients to compare how their UI status is after treatment with how it was before 
treatment.
14
 Seven responses are possible: very much better, much better, a little better, no change, a little 
worse, much worse, and very much worse. The Incontinence Quality of Life questionnaire, a validated 22-
item UI-specific quality-of-life questionnaire on which higher scores indicate better quality of life, was also 
administered.
15,16
 Participants also submitted their 72-hour bladder diary at this time. After consulting with 
their physician, all patients received a teaching session and standardized 12-week behavioral home 
management program including pelvic floor muscle training, distraction techniques, and lifestyle 
modification recommendations. Some patients also received pharmacological interventions or were 
scheduled for surgery. 
 
At the 3-month follow-up visit, the same research assistant met with the patients to determine the patients' 
global impression of improvement in their UI condition using the PGI-I, to collect the second bladder diary, 
and to re-administer the GSE-UI and the Incontinence Quality of Life questionnaire. Afterward, patients 
met with their physician to discuss treatment effectiveness, and the physician was asked to document the 
Clinician's Global Impression of Improvement (CGI-I). The CGI-I is a clinician-rated single-item scale that 
uses the same 7-point response criteria as the PGI-I.
17
 Physicians were blinded to all of the outcome scores 
collected specifically for this study. The clinician's diagnosis was used to classify UI type based on the 
patient's history and physical examination. The institutional review board of the Institut Universitaire de 
Gériatrie de Montréal, Quebec, Canada, approved the study. 
 
Analysis 
For each participant, the total score on the GSE-UI was calculated by summing the scores from each of the 
12 items (minimum 0, maximum 10 points per item, range of total score 0–120). If one or more items were 
scored as “does not apply to me,” the item was omitted, and the total index score, calculated based on the 
number of items completed, was recalibrated on a scale of 120. To calculate a combined PGI-I and CGI-I 
score, each of the response options was assigned a numerical value from 1 to 7. An average of the two 
values was taken and rounded to the nearest full number, and then the average score for each participant 
was recategorized according to the original set of response options. 
Guyatt's change index, applied to the total GSE-UI score, was used to test responsiveness. Guyatt's change 
index defined as the mean change in score in an improvement group divided by the standard deviation of 
the change in score in a stable group was used.
18–20
 The stable group for this study was defined as 
participants who reported no change in UI status on the PGI-I during the week between baseline 
administrations of the 12-item GSE-UI. Two types of improvement groups were calculated using the 3-
month follow-up data: patients experiencing “clinically meaningful improvement” and those experiencing 
“any improvement.” A participant was considered to have experienced a “clinically meaningful 
improvement” if the PGI-I and CGI-I ratings both indicated “very much better” or if one of the two ratings 
was “very much better” and the other “much better.” A participant was considered to have experienced 
“any improvement” if any other combination of “very much better,”“much better,” or “a little better” was 
obtained. Classifying the improvement groups for the responsiveness testing using a combination of PGI-I 
and CGI-I ratings of patients and physicians is an accepted method that has been used previously in other 
chronic disease states.
21,22
 Guyatt statistics of 0.20, 0.50, and 0.80 or greater have been used to represent 
small, moderate, and large responsiveness, respectively.
20 
 
The clinical utility of the index was determined by selecting GSE-UI cutoff scores for improvement that 
simultaneously maximized the sensitivity and specificity for correctly classifying patients according to 
whether they fell in the clinically meaningful change group or the any improvement group. To do this, 
receiver operating characteristic (ROC) curves were constructed separately for each definition of 
improvement—the “clinically meaningful improvement” group and the “any improvement”—by plotting 
the sensitivity versus 1–specificity of different GSE-UI cutoff change scores for identifying members of 
each group.
19
 The ROC data point closest to the upper left-hand corner of each curve was used to indicate 
the most efficient cutpoint for differentiating patients whose UI status improved a specific amount (e.g., 
very much better) from those whose UI status had not changed by the specified amount.
22
 The area under 
each ROC curve designates the probability of selecting the patient who improved by this specified amount 
from a set of two patients, one of whom did not improve by the specified amount. Specifically, the 
“clinically meaningful improvement” group was compared with all other patients, and the “any 
improvement” group was compared with those patients who experienced no change or worsening UI. 
To assess the longitudinal validity of the GSE-UI, mean GSE-UI scores for the different response options 
of the combined PGI-I and CGI-I ratings were compared with self-reported changes in the mean number of 
UI episodes per day calculated from the bladder diaries, as well as changes in quality-of-life scores on the 
baseline and follow-up Incontinence Quality of Life questionnaires. Correlation between the change scores 
was assessed using Pearson correlation coefficients (r). Nine patients did not reliably complete their 72-
hour voiding diaries, and these were excluded from the longitudinal validity analyses. 
 
RESULTS 
Four hundred fifty consecutive newly referred patients were screened for study eligibility. Two hundred 
twenty-two patients were excluded; 112 did not experience UI, an additional 84 were younger than 65, and 
26 met other exclusion criteria. Of the 228 eligible patients, 89 (39.0%) agreed to participate in 
responsiveness testing. The three most common reasons for refusing to participate were disinterest in 
becoming a research subject (33.2%), busy schedules (25.1%), and poor health status (15.4%). Baseline 
characteristics of the study participants are shown in Table 1. The study group comprised mainly older 
females with variable UI severity and a predominance of mixed UI type. All patients received a teaching 
session and 12-week behavioral home management program consisting of pelvic floor muscle training, 
distraction techniques, and lifestyle modification recommendations. In addition, 21.4% of patients received 
anticholinergic agents to treat urge symptoms, and 15.6% were scheduled for stress incontinence surgery. 
UI data on eligible patients who refused to participate were not available for comparison. 
 
 
Table 1.    Participant Characteristics (N=89) 
 
Characteristic 
Value 
 
1. SD=standard deviation; UI=urinary incontinence. 
Age, mean ± SD (range) 72.6+5.8 (65–90) 
Sex, % 
 Male 3.2 
 Female 96.8 
Language, % 
 French 88.9 
 English 11.1 
Educational attainment, % 
 <High school 15.1 
 High school 51.7 
 University 33.2 
Mini-Mental State Examination score, 
mean ± SD (range) 
28.9 ± 1.1 (24–30) 
General health status, % 
 Excellent 17.2 
 Very good 36.0 
 Good 37.6 
 Fair 9.2 
 Poor 0 
Duration of urinary incontinence symptoms, years, % 
 <1 3.9 
 1–5 61.7 
 >5 34.4 
Frequency of UI episodes, % 
 ≤1 times/week 9.2 
 2–3 times/week 15.3 
 1 time/day 20.2 
 Several times a day 52.6 
 All the time 2.7 
Amount of urine loss per episode, % 
 A small amount 61.6 
 A moderate amount 29.0 
 A large amount 9.4 
Number of pads used per day, % 
 None 15.1 
 1 33.7 
 2–3 38.9 
 ≥4 12.3 
Bladder diary: number of UI episodes 
per day, mean ± SD, median (range) 
2.3 ± 2.4, 2.0 (0–12) 
  
 
Responsiveness 
At 3-month follow-up, 20 (22.5%) of patients were “very much better,” 37 (41.6%) were “a little or much 
better,” 23 (25.8%) had experienced no change, and nine (10.1%) were worse. Table 2 shows the mean 
GSE-UI improvement scores according to each improvement rating. Using the standard deviation of the 
GSE-UI change scores in the stable group at baseline (n=62, mean change 1.9±8.6), the Guyatt's change 
index for the GSE-UI was calculated as 2.6 for the clinically meaningful improvement group, and 1.5 for 
the any improvement group. 
 
 
 
 
 
Geriatric Self-Efficacy for Urinary 
Incontinence total score (range 0–120), 
mean ± SD, median (range) 
65.8 ± 26.2, 68.1 (4–110) 
Incontinence Quality of Life total 
score (range 0–100), mean ± SD, 
median (range) 
65.3 ± 23.1, 70.4 (2–99) 
UI specialist diagnosis, % 
 Stress 24.7 
 Urge 19.1 
 Mixed 55.2 
 Obstruction 1.0 
UI treatment, % 
 Behavioral 100.0 
 Pharmacologic 21.4 
 Surgical 15.6 
Table 2.    Geriatric Self-Efficacy Index for Urinary Incontinence (GSE-UI) Scores According to the 
Combined Patient's and Clinician's Global Impressions of Improvement 
 
 
 
Improvement 
Level at 
3-Month 
Follow-Up 
GSE-UI 
Initial Follow-Up Change 
Mean ± Standard Deviation 
1. Note: Higher scores indicate greater self-efficacy for preventing unwanted urine loss. 
All participants 
(N=89) 
65.8 ± 26.2 71.5 ± 29.0 5.8 ± 21.6 
Very much 
better (n=20) 
70.6 ± 23.3 92.8 ± 14.4 22.3 ± 24.9 
Much better 
(n=20) 
77.4 ± 21.4 85.0 ± 23.0 7.6 ± 16.1 
A little better 
(n=17) 
66.0 ± 24.9 75.1 ± 19.3 9.1 ± 14.9 
No change 
(n=23) 
58.1 ± 28.6 54.9 ± 25.0 −3.2 ± 16.6 
A little worse 
(n=8) 
47.6 ± 30.0 31.6 ± 28.1 −16.0 ± 15.8 
Much worse 
(n=1) 
55.2 18.0 −37.2 
Clinically 
meaningful 
improvement 
group (n=20) 
70.6 ± 23.3 92.8 ± 14.4 22.3 ± 24.9 
Any 
improvement 
71.6 ± 23.2 84.8 ± 20.2 13.2 ± 20.2 
Improvement 
Level at 
3-Month 
Follow-Up 
GSE-UI 
Initial Follow-Up Change 
Mean ± Standard Deviation 
group (n=57) 
 
Clinical Utility 
Results of the ROC curves revealed an improvement of 14 points or greater on the GSE-UI to be most 
efficient for identifying patients who had improved by a clinically meaningful amount, with a sensitivity of 
75.1% and a specificity of 78.2%. The area under the curve for the 14-point cutoff ROC curve was 0.76, 
indicating a 76.0% probability of selecting correctly between two patients, one of whom was very much 
better and the other not. For identifying patients who had experienced any degree of improvement, a 5-
point increase on the GSE-UI proved to be the best cutoff score, with a sensitivity of 70.0%, a specificity of 
78.3%, and a 79.0% probability of selecting a patient who improved by any amount from a set of two 
patients, one of whom did not improve by any amount. 
Longitudinal Validity 
Changes in the GSE-UI correlated strongly with changes in Incontinence Quality of Life scores 
(r=0.7,P<.001) and moderately with reductions in UI episodes as recorded in the bladder diary 
(r=0.4,P=.004). 
  
DISCUSSION 
These findings show that the 12-item GSE-UI is responsive and clinically useful for older adults 
experiencing UI. As a research tool, it can now be used in studies investigating self-efficacy as an 
explanatory psychological mechanism for improving UI status or for testing interventions that may 
influence self-efficacy. In practice, if it is used as an outcome measure, health providers will be able to 
interpret a minimal 14-point increase on the GSE-UI as evidence of a clinically meaningful treatment 
result. Change scores of 5 to 13 points on the GSE-UI might suggest that alternative management should be 
pursued. If no change or worsening UI occurs at follow-up, then a reevaluation of the treatment approach 
and a review of possible multifactorial factors contributing to UI should be undertaken. 
The choice of a criterion standard indicator for clinically meaningful improvement in UI is complex, 
because no consensus exists for what constitutes meaningful change in the absence of cure. Because UI is 
primarily a condition that affects quality of life, many would argue that only the patient's impression of 
improvement should be considered when determining clinically meaningful change, but responsiveness 
testing for many other chronic condition instruments have traditionally taken into account the patient's, 
physician's, and caregiver's opinions.
21–23
 For the current study, both methods (using only the patient's 
opinion vs the combined rating) were compared, and virtually identical results were found, with a 
recategorization of only five patients using the patient's global impression–only approach. Because patient 
ratings of improvement could not be ascertained independently of their responses to the GSE-UI in this 
study, it was decided to report the results using the combined rating. 
 
The choice of Guyatt's statistic for determining responsiveness of the GSE-UI also warrants comment. 
Other studies have arbitrarily used the effect size, the standardized response mean, or other definitions of 
Guyatt's statistic for evaluating the responsiveness of instruments.
16,20,23
 Measures of effect size and 
standardized response means are usually used for single-group designs.
22
 Guyatt's responsiveness statistic, 
by comparison, has the advantage of being able to account for intragroup variability over time within a 
stable group of patients in the denominator of the equation. This study was designed to first test for 
differences over time within a stable group before implementing the intervention, and it was thus possible 
to evaluate the responsiveness of the GSE-UI using this latter definition of Guyatt's statistic. Other 
investigators prefer a more-complicated version of Guyatt's statistic,
20
 but because of the difficulties 
involved in defining a minimal clinically important change in UI status, it was decided to present the 
analyses as described. 
 
Limitations of this study include the low participation rate (39%). Because it was not possible to measure 
self-efficacy in patients who refused to participate, it is not known whether their level of self-efficacy could 
have played a role in this refusal. Theoretically, eligible participants who cited busy schedules or disinterest 
in becoming research subjects as reasons for not participating could have had higher levels of self-efficacy 
than those who agreed to participate. Patients who cited poor health as a reason for refusing to participate 
may have had lower self-efficacy levels as a consequence of living with multiple acute or chronic diseases. 
Exclusion of these groups of participants from the analyses may have affected the responsiveness estimates 
for the GSE-UI. In addition, the self-efficacy questionnaire was completed under supervised guidance in 
this study, and thus its performance under self-administrated conditions was untested. Finally, the GSE-UI 
will not be useful for patients with cognitive impairment, a frequent co-phenomenon of UI in older adults. 
In conclusion, this study shows that the 12-item GSE-UI is responsive and clinically useful as a new 
outcome measure for future research and practical outcome management of UI in elderly people. Its focus 
on an important psychological factor related to UI may help clarify the factors and mechanisms underlying 
dysfunctional urinary habits and their resolution in older adults. 
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Appendix 
 
Table Appendix Table A1.    12-Item Abridged Version of the Geriatric Self-Efficacy for Urinary 
Incontinence 
Question 
Score 
(out of 10) 
How confident are you that you can hold in your 
urine … 
  
1. when you are at home and have to go to the bathroom?   
2. when you are away from home?   
3. long enough to get to the bathroom in time during the 
night? 
  
4. for at least 20 minutes when you feel the urge?   
5. when coughing?   
6. when sneezing?   
7. when laughing?   
8. when you are nervous?   
How confident are you that you can …   
9. visit places where you may have difficulty locating the 
bathroom? 
  
10. go out on social outings without worrying about urine 
loss? 
  
11. prevent urine loss without relying on pads or protection 
when you are at home? 
  
Question 
Score 
(out of 10) 
How confident are you that you can hold in your 
urine … 
  
12. prevent urine loss without relying on pads or protection 
when you are out? 
  
Total Score   
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